These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26774016)

  • 21. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
    Carris NW; Taylor JR; Gums JG
    Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
    Hanefeld M; Raccah D; Monnier L
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.
    Fleischmann H; Göke R; Bramlage P
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S91-S97. PubMed ID: 27986406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump.
    Cohen O; Filetti S; Castañeda J; Maranghi M; Glandt M
    Diabetes Care; 2016 Aug; 39 Suppl 2():S180-6. PubMed ID: 27440831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.
    Charbonnel PB
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S1-6S2. PubMed ID: 26774014
    [No Abstract]   [Full Text] [Related]  

  • 29. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Esposito K; Giugliano D
    Diabetes Obes Metab; 2018 Sep; 20(9):2309-2313. PubMed ID: 29732679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
    Lisco G; De Tullio A; Disoteo O; De Geronimo V; Piazzolla G; De Pergola G; Giagulli VA; Jirillo E; Guastamacchia E; Sabbà C; Triggiani V
    Front Endocrinol (Lausanne); 2022; 13():920541. PubMed ID: 36157450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
    Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.
    Gomez-Peralta F; Al-Ozairi E; Jude EB; Li X; Rosenstock J
    Diabetes Obes Metab; 2021 Jul; 23(7):1445-1452. PubMed ID: 33651460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus.
    Raccah D; Huet D; Dib A; Joseph F; Landers B; Escalada J; Schmitt H
    Diabet Med; 2017 Sep; 34(9):1193-1204. PubMed ID: 28574177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.
    Wysham CH; Lin J; Kuritzky L
    Postgrad Med; 2017 May; 129(4):436-445. PubMed ID: 28294702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabet Med; 2017 Feb; 34(2):213-222. PubMed ID: 27279380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GLP-1 as a target for therapeutic intervention.
    Rajeev SP; Wilding J
    Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.